Q-omics provides the consensus-scored RPL21P23 profile across patient tissues and cancer cell-line models. RPL21P23 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RPL21P23 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RPL21P23 RNA expression shows 8,917 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, THCA, and CCRCC as cancer lineages where RPL21P23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P23 survival associations across molecular data types. RPL21P23 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P23 RNA expression–survival associations across cancer types. High RPL21P23 expression shows unfavorable associations in ACC, SKCM, PAAD and KIRP, but favorable associations in HNSC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for RPL21P23 RNA expression.
This table summarizes RPL21P23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P23 shows lower tumor expression in THCA, KICH, BRCA, LUSC and LIHC and higher tumor expression in KIRC. The THCA box plot shows higher RPL21P23 RNA expression in normal versus tumor tissue (log2 FC = −0.238, t-test p = .003).
This table shows molecular features associated with RPL21P23 in patient tissues and cancer cell lines. In patient samples, RPL21P23 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
